Literature DB >> 12634405

The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

Tonie Cilliers1, Jabulani Nhlapo, Mia Coetzer, Dragana Orlovic, Thomas Ketas, William C Olson, John P Moore, Alexandra Trkola, Lynn Morris.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) subtype C viruses with different coreceptor usage profiles were isolated from 29 South African patients with advanced AIDS. All 24 R5 isolates were inhibited by the CCR5-specific agents, PRO 140 and RANTES, while the two X4 viruses and the three R5X4 viruses were sensitive to the CXCR4-specific inhibitor, AMD3100. The five X4 or R5X4 viruses were all able to replicate in peripheral blood mononuclear cells that did not express CCR5. When tested using coreceptor-transfected cell lines, one R5 virus was also able to use CXCR6, and another R5X4 virus could use CCR3, BOB/GPR15, and CXCR6. The R5X4 and X4 viruses contained more-diverse V3 loop sequences, with a higher overall positive charge, than the R5 viruses. Hence, some HIV-1 subtype C viruses are able to use CCR5, CXCR4, or both CXCR4 and CCR5 for entry, and they are sensitive to specific inhibitors of entry via these coreceptors. These observations are relevant to understanding the rapid spread of HIV-1 subtype C in the developing world and to the design of intervention and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634405      PMCID: PMC150635          DOI: 10.1128/jvi.77.7.4449-4456.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  New targets for inhibitors of HIV-1 replication.

Authors:  J P Moore; M Stevenson
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

Review 2.  HIV fusion and its inhibition.

Authors:  C C LaBranche; G Galasso; J P Moore; D P Bolognesi; M S Hirsch; S M Hammer
Journal:  Antiviral Res       Date:  2001-05       Impact factor: 5.970

3.  Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0.

Authors:  P Swanson; V Soriano; S G Devare; J Hackett
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein.

Authors:  N Shimizu; Y Haraguchi; Y Takeuchi; Y Soda; K Kanbe; H Hoshino
Journal:  Virology       Date:  1999-07-05       Impact factor: 3.616

5.  Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Authors:  A Trkola; T J Ketas; K A Nagashima; L Zhao; T Cilliers; L Morris; J P Moore; P J Maddon; W C Olson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse.

Authors:  D Unutmaz; W Xiang; M J Sunshine; J Campbell; E Butcher; D R Littman
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

7.  Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.

Authors:  C W Hendrix; C Flexner; R T MacFarland; C Giandomenico; E J Fuchs; E Redpath; G Bridger; G W Henson
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.

Authors:  Y Zhang; B Lou; R B Lal; A Gettie; P A Marx; J P Moore
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

9.  Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project.

Authors:  M Clerici; S Butto; M Lukwiya; M Saresella; S Declich; D Trabattoni; C Pastori; S Piconi; C Fracasso; M Fabiani; P Ferrante; G Rizzardini; L Lopalco
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

10.  Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone.

Authors:  T Ndung'u; B Renjifo; M Essex
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

View more
  69 in total

1.  Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Authors:  Mia Coetzer; Rebecca Nedellec; Tonie Cilliers; Tammy Meyers; Lynn Morris; Donald E Mosier
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

2.  Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.

Authors:  Georgios Pollakis; Almaz Abebe; Aletta Kliphuis; Moustapha I M Chalaby; Margreet Bakker; Yohannes Mengistu; Margreet Brouwer; Jaap Goudsmit; Hanneke Schuitemaker; William A Paxton
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia.

Authors:  Sandra Gonzalez; Clement Gondwe; Damien C Tully; Veenu Minhas; Danielle Shea; Chipepo Kankasa; Tendai M'soka; Charles Wood
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

4.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

6.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

8.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

9.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

10.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.